The non-profit Global Drug Facility (GDF), a division of the Stop TB Partnership, has announced a price reduction for the life-saving drug used to treat drug-resistant tuberculosis (DR-TB) — bedaquiline. A full treatment course produced by Lupin will now be available at USD 63, representing a 30% decrease, while the cost of the full BPaL(M) regimen will fall below USD 300, down to USD 284 per course.

According to experts, this price cut will generate more than USD 4.5 million in annual savings for high TB burden countries and GDF clients. The savings could be used to procure an additional 71,000 courses of bedaquiline or 16,000 full BPaLM regimens each year.

This marks the third consecutive price reduction for key DR-TB medicines in 2025. In February, GDF announced a 54% price cut for bedaquiline, followed by a 25% price reduction for pretomanid in April. As a result, six WHO-recommended DR-TB regimens are now priced below USD 300, including the endTB 9BLMZ regimen, which for the first time has dropped below USD 200 — now priced at USD 173 per course.

“2025 has been full of challenges, but we don’t give up. Today we are announcing the lowest price for DR-TB treatment regimens in history! In today’s financial environment, where every penny counts, this is a huge achievement. Now it is crucial to match this success with the same level of commitment to diagnosing and treating people with DR-TB,” said Dr. Lucica Ditiu, Executive Director of the Stop TB Partnership.